Clinical trials: Metastatic Solid Tumor Cancer
Cancer, Solid Tumor
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
The present study has 5 parts. In Parts A and A1, the dose of intravenous (IV) pembrolizumab (MK-3475) will be escalated from 1 to 10 mg/kg to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for…
- Trial name
- KEYNOTE-001 (NCT01295827)
- Testing
- Pembrolizumab
- Volunteers
- 1,260 people
- Sponsor
- Merck Sharp & Dohme LLC
NSCLC, Breast Cancer
A Study of YL202 in Selected Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.
- Conditions
- NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT06107686
- Testing
- YL202 should be intravenously infused
- Where
- 82 sites in China
- Volunteers
- 200 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)
This was a Phase 1, open-label, dose-escalation trial of avelumab (antibody targeting programmed death ligand 1 [anti PD-L1]) in Japanese participants with metastatic or locally advanced solid tumors, followed by a consecutive…
- Trial name
- NCT01943461
- Testing
- Avelumab 3 mg/kg, Avelumab 10 mg/kg, Avelumab 20 mg/kg
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Carcinoma, Non-small-Cell Lung
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in…
- Trial name
- PALOMA-2 (NCT05498428)
- Testing
- Amivantamab, Lazertinib, Carboplatin
- Where
- 110 sites in United States, Brazil and 10 more
- Volunteers
- 520 people
- Sponsor
- Janssen Research & Development, LLC
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Esophageal Cancer, Advanced Lung Cancer
A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002
The goal of this clinical trial is to learn if ADC drug MC002 works to treat locally advanced/metastatic solid tumors in adults. It will also learn about the safety of MC002.
- Trial name
- NCT07726212
- Testing
- MC002（ADC）
- Volunteers
- 143 people
- Sponsor
- Hangzhou MacroLink Biopharmaceutical LLC
Solid Tumor
SHR-1701 in Metastatic or Locally Advanced Solid Tumors
The main purpose of this Phase I study is to access the safety and tolerability of SHR-1701 at different dose levels. It is hoped to find out the recommended dose for Phase II/III.
- Trial name
- NCT03710265
- Testing
- SHR-1701
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors
HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the safety/tolerability、the pharmacokinetic profile and efficacy of HS-10365 in Chinese advanced solid tumor…
- Trial name
- NCT05207787
- Testing
- HS-10365
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks.
- Trial name
- NCT06517433
- Testing
- upifitamab rilsodotin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Mersana Therapeutics
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Locally Advanced or Metastatic Malignant Solid Tumors
A Study of WJ05129 in Advanced Malignant Solid Tumors
This study was an open, multicenter Phase I/II clinical study of WJ05129 in patients with locally advanced or metastatic malignant solid tumors in China, which was divided into three stages: Single-dose escalation,Combined dose…
- Trial name
- NCT05326035
- Testing
- WJ05129, Paclitaxel injection
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Suzhou Junjing BioSciences Co., Ltd.
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Urothelial Carcinoma, Renal Cell Carcinoma
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
- Trial name
- NCT05661955
- Testing
- BGB-A445, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 113 people
- Sponsor
- BeiGene
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma
- Trial name
- NCT07903415
- Testing
- PF-08098488
- Where
- 4 sites in United States
- Volunteers
- 280 people
- Sponsor
- Pfizer
Advanced Solid Tumors, Metastatic Solid Tumors
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors…
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
- Trial name
- NCT07397338
- Testing
- Daraxonrasib, Elironrasib, Zoldonrasib
- Where
- 19 sites in United States
- Volunteers
- 370 people
- Sponsor
- Revolution Medicines, Inc.
Neoplasm Metastasis
A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
The purpose of this study is to evaluate the safety, tolerability, and efficacy in participants with advanced/metastatic or recurrent malignancies who receive gebasaxturev (V937) in combination with pembrolizumab (MK-3475).
- Trial name
- NCT04521621
- Testing
- Gebasaxturev, Pembrolizumab
- Where
- 29 sites in United States, Canada and 12 more
- Volunteers
- 76 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy.
- Trial name
- NCT05155332
- Testing
- BI 1831169, anti-PD-1 antibody
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 190 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors, Non-Hodgkin Lymphoma
Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
This is a Phase 1, open-label, dose-escalation, multicenter study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma.
- Trial name
- NCT03707093
- Testing
- ADG106
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Adagene Inc
Solid Tumor, Adult, Advanced Solid Tumor
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT04761198
- Testing
- Etigilimab, Nivolumab
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 76 people
- Sponsor
- Mereo BioPharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.